Managing High Cholesterol in Primary Care · 2020-03-18 · 2 Managing High Cholesterol in Primary...
Transcript of Managing High Cholesterol in Primary Care · 2020-03-18 · 2 Managing High Cholesterol in Primary...
2
Managing High Cholesterol in Primary Care
Introduction
In 2014, 263 million prescriptions were written for lipid-lowering drugs at an annual cost of
approximately $13.7 billion.1 Nevertheless, less than half of those medically eligible for treatment
of high cholesterol currently receive medication, even among high-risk patients, despite widely-
accepted guidelines for management and solid evidence to guide therapy.2,3
Primary care physicians are on the front lines of advancing care for patients at risk of
atherosclerotic cardiovascular disease (ASCVD), and the management of high cholesterol levels
is a key element in that effort. In recent years, clinical studies and professional guidelines have
reconsidered the approach to cholesterol-lowering medications and have changed the paradigm
for assessment and treatment of patients with high cholesterol.4-6
This clinical brief summarizes current practice guidelines and the evidence base on which those
guidelines are based. This brief focuses on statins because the evidence supporting their use to
reduce risk of CVD is particularly strong. We will, however, briefly review the evidence on non-
statin lipid-lowering drugs and provide guidance for using these agents to lower ASCVD risk.
Epidemiology
While the prevalence of hyperlipidemia has declined slightly in the past 20 years, about half of all
adults in the U.S. have at least “borderline high-risk” cholesterol levels and about one-third of all
adults have elevated LDL cholesterol.3 According to the third report of the National Cholesterol
Education Program on the detection, evaluation, and treatment of high blood cholesterol in adults
(ATP III) published in 2003, optimal levels of cholesterol are considered to be LDL < 100 mg/dL
(and < 70 mg/dL in some high-risk individuals) and total cholesterol < 200 mg/dL. The more
recent cholesterol guidelines published in 2013 by the American College of Cardiology and the
American Heart Association do not identify optimal cholesterol levels, but instead promote the
importance of risk stratification, which will be discussed in more detail below. Importantly, a
graded and continuous association exists between serum LDL concentration, atherosclerosis
progression, and cardiovascular mortality (Figure 1).7
3
Figure 1: Association between cardiovascular disease and LDL cholesterol levels7
Oklahoma suffers from particularly high rates of CVD, as illustrated in the following statistics:
8
In 2011, Oklahoma men had the second worst heart disease death rate in the nation,
and Oklahoma women had the third worst rate.
In 2012 heart disease was the leading cause of death among all adults in Oklahoma.
According to the Oklahoma State Department of Health, however, nearly half of heart disease
deaths among Oklahoma males, and a third of heart disease deaths among Oklahoma females
are potentially preventable.8
Treatment overview
All guidelines for the treatment of hypercholesterolemia stress the importance of encouraging and
supporting healthy eating habits, increased physical activity, and the maintenance of a normal
BMI in patients, and interventions to meet these goals have been shown to produce modest, yet
potentially significant, results. In overweight patients, there is a dose-response relationship
between the amount of weight lost and the improvement in lipid profile.9 For example, a 3 kg
weight loss is associated with a mean reduction in triglycerides of at least 15 mg/DL, and a 5– 8
kg weight loss is associated with LDL-C reductions of about 5 mg/dL, and HDL-C increases of 2-3
mg/dL.9 Adopting a diet high in cholesterol-lowering foods, such as plant sterols, viscous fibers,
and soy protein can reduce LDL-C by up to 13%.10
For many patients, however, lifestyle changes are insufficient, or difficult to sustain on a long-term
basis. When lifestyle changes alone fail to lower LDL to normal levels, abundant evidence
supports treating hypercholesterolemia with statins to reduce cardiovascular mortality in patients
with and without known coronary artery disease.11,12,13
Primary prevention
Three landmark trials demonstrated that statins lower cholesterol levels and reduce the risk of
CVD events, including CVD mortality, in patients without pre-existing CVD.
4
The 1995 West of Scotland Coronary Prevention Study (WOSCOPS) of 6595 middle-aged men
randomized to either pravastatin 40 mg, or placebo and followed for about 5 years showed a 33%
relative reduction of coronary mortality (1.9% versus 1.3%; P=0.04) in the pravastatin group
compared to placebo.13
Major coronary events (nonfatal MI or death from CHD) were 31% lower
in the pravastatin participants compared to the placebo group.
The Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPs) of
approximately 6600 men and women with no history of CAD randomized participants to lovastatin
(20-40 mg) or placebo with both arms receiving low saturated fat and low cholesterol diet
intervention.14
After an average follow-up of 5.2 years, lovastatin reduced LDL levels by about
25% and reduced the incidence of first major coronary events (fatal or nonfatal MI, unstable
angina, or sudden cardiac death) by 37% (RR 0.63; 95% CI: 0.50-0.79). There were too few
events to perform a survival analysis on coronary mortality.
The Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA) of 10,300
patients was stopped after 3 years due to a 36% relative reduction of nonfatal MI or CHD
mortality and a 21% relative reduction in total cardiovascular events in the atorvastatin treated
participants, whose baseline LDL level was reduced from 131 mg/dL to 88 mg/dL.15
More recently, a 2011 Cochrane meta-analysis of 14 studies of statin use for primary prevention
published between 2001 and 2007 found that statins reduced all-cause mortality by 14% (OR
0.86, 95% CI 0.79 to 0.94) and reduced combined cardiovascular endpoints by 30% (RR 0.70;
95% CI: 0.61-0.79).16
A 2012 individual patient-level analysis pooled data for 174,149 participants
from 27 trials and stratified patients by 5-year risk of major CV event.17
On average, patients
treated with statins who experienced a 39 mg/dL reduction in LDL had a 21% reduction in major
CVD events (RR 0.79; 95% CI: 0.77-0.81), an association that held true even for the 2 lowest risk
groups.
Taken together, these trials suggest that statins for primary prevention are effective over a wide
range of LDL-C levels and provide a similar relative risk reduction as has been observed in
secondary prevention trials (see Figure 2 below).
Secondary prevention
Meta-analyses of the effect of treatment in patients with known coronary artery disease have
found a reduction in the absolute risk of death of about 15%.18,19
A review of primary and
secondary prevention trials found that every 10% decrease in serum cholesterol was associated
with a 15% decrease in coronary heart disease mortality and an 11% decrease in total mortality
risk, with no change in non-cardiac mortality.20
Finally, a meta-analysis of data from >90,000
patients with known CVD risk found that statin therapy can reduce the 5- year incidence of major
coronary events, coronary revascularization, and stroke by about 20% per 39 mg/dL reduction in
LDL levels.21
The absolute benefit relates mainly to the patient’s absolute risk level and to the
absolute reduction in LDL cholesterol achieved.21
5
Figure 2: Patients treated with statins for primary or secondary prevention of ASCVD have
significant reduction of major CV events, across a wide range of risk17
ASCVD risk assessment
The 2003 Adult Treatment Panel III guidelines recommended treating patients with statins who
had certain high-risk clinical comorbidities (such as coronary artery disease or diabetes) or who
were at high risk of developing ASCVD over 10-years, as assessed by the Framingham Risk
Score. The Framingham risk score uses variables such as age, gender, cholesterol levels,
smoking status, and hypertension to predict the risk of fatal or non-fatal MI and is well validated in
European and American populations.22
6
Subsequent risk scores have been developed that use additional risk factors as well as alternate
end-points. The Reynolds risk score, developed in 2007, includes family history of CHD and high-
sensitivity-CRP levels.23,24
The Framingham risk score has been modified to predict global CVD
events, including coronary events, stroke, claudication, and incident heart failure.25
Most of these
risk scores were derived in predominately white populations and later validated in cohorts with
white and black patients. Using these tools, cardiovascular risk tends to be overestimated in
certain ethnic groups, including Hispanic and Japanese-American men, Native-American women,
and Chinese men and women.26
The 2013 Pooled Cohort ASCVD Risk Equations (ASCVD calculator), released as part of the
2013 ACC/AHA cholesterol guidelines, was developed to approximate CVD risk in a racially
diverse patient population using data pooled from the Framingham cohort as well as the ARIC
and CARDIA studies. The calculator predicts 10-year risk of “hard” cardiovascular end-points,
including coronary heart disease death, non-fatal MI, and fatal and non-fatal stroke among white
and non-Hispanic blacks. Similar to prior risk scores, the ASCVD calculator overestimates
cardiovascular risk in Hispanic and Asian-Americans.5 Even among white and black populations,
several studies have suggested that the ASCVD calculator more generally overestimates
cardiovascular risk compared to the Framingham-based calculators.27
Of note, these calculators
have never been tested against each other in an RCT.
The 2013 ACC/AHA cholesterol guidelines recommend using the ASCVD calculator, and further
recommend using a 7.5% or greater 10-year risk of ASCVD as a threshold for initiating statins for
primary prevention. This is a lower threshold than that suggested in prior guidelines but
represents a more meaningful balance of statin risk versus benefit. Some authors have
suggested a higher 10-year ASCVD risk threshold, such as 10% or 12.5%, for statin initiation.28
The risk of developing diabetes from statin treatment is estimated to be 1 in 1000 per year for
low-intensity statin and 3 in 1000 per year for high-intensity statin.6 In this setting, 100 patients
with a 10-year risk of ASCVD of 10% would need to take a moderate-dose statin daily for 10
years to prevent two heart attacks; among these patients, one would develop diabetes as a result
of statin therapy.4
The new cholesterol guidelines make two important recommendations:
1. Clinicians should use shared decision making with the patient when discussing statin
initiation for primary prevention. The discussion should include potential for ASCVD risk
reduction, adverse effects such as muscle aches and diabetes, and patient preferences.
2. A 10-year ASCVD risk of 7.5% should be used as a guideline for initiating the discussion
about statin initiation and should not be used as an absolute threshold.
Among patients with borderline ASCVD risk (10-year risk 5-10%) or among patients with an
uncertain risk-benefit profile, the presence of one or more of the following risk factors may lower
the threshold for statin initiation:6
LDL ≥ 160 mg/dL
Family history of premature ASCVD (< 55 years in 1st degree male relative or < 65 years
in 1st degree female relative)
High-sensitivity C-reactive protein ≥ 2 mg/L
Coronary artery calcium score ≥ 300 Agatston units
7
Ankle brachial index < 0.9
Elevated lifetime risk of ASCVD
A 2015 longitudinal community-based cohort study of 2435 statin-naïve participants found that
the ACC/AHA guidelines for determining statin eligibility, compared with the ATP III, were
associated with greater accuracy and efficiency in identifying increased risk of incident CVD and
subclinical coronary artery disease, particularly in intermediate-risk participants.29
The use of a clinical decision aid may be helpful in discussing the risks and benefits of statin
therapy. The Mayo Clinic Decision aid (http://statindecisionaid.mayoclinic.org) facilitates the use
of the ASCVD, ATP-III, and Reynolds risk calculators.
Table 3: Common cardiovascular risk calculators
Risk Score Outcome Characteristics
ASCVD Risk Calculator CHD death, non-fatal MI, and fatal and non-fatal stroke
Derived in racially diverse cohort. Outcomes are “hard” CV endpoints that patients care about
Framingham Risk Score (ATP-III calculator)
Fatal and non-fatal MI Statin initiation threshold previously recommended at 20%. Using a lower threshold is reasonable.
Framingham Risk Score (Global CVD)
Coronary events, cerebrovascular events, PAD, heart failure
May be helpful to provide global CV risk to patients
Reynolds Risk Score MI, ischemic stroke, coronary revascularization, or CV death
Includes family history, diabetes status, and hs-CRP levels in risk calculation
MI: myocardial infarction. PAD: peripheral arterial disease. CV: cardiovascular Coronary events: MI, coronary death, acute coronary syndrome, angina; Cerebrovascular events: ischemic or hemorrhagic stroke, transient ischemic attack; PAD: intermittent claudication.
The ASCVD risk calculator: http://tools.cardiosource.org/ASCVD-Risk-Estimator/
Framingham Risk Score (ATP-III Calculator): http://cvdrisk.nhlbi.nih.gov/
Framingham Risk Score (Global CVD): http://www.framinghamheartstudy.org/risk-
functions/cardiovascular-disease/10-year-risk.php
Reynolds Risk Score: http://www.reynoldsriskscore.org/
8
Testing lipid levels
The two main guidelines for lipid screening make similar recommendations, with small points of
difference. The 2013 ACC/AHA guidelines are based on cholesterol screening beginning at age
40 and continuing every 5 years until age 79 for individuals without clinical ASCVD.5 The U.S.
Preventive Services Task Force (USPSTF) recommends initiating screening in men at age 35
years, and in women at age 45 years, except for patients with increased risk for cardiovascular,
for whom the starting age is 20.30
A repeat screening interval of 5 years is suggested for low-risk
individuals, with a shorter interval in those with borderline results.
Fasting or non-fasting lipid screening?
Current guidelines recommend a fasting lipid profile in order to calculate the LDL cholesterol level
(LDL cholesterol = total cholesterol − HDL cholesterol − [triglycerides ÷ 5]). In non-fasting states
LDL and triglyceride levels can vary by as much as 20%.31
However, some patients do not
undergo lipid testing due to the inconvenience of fasting or early morning blood draws. Given the
possible benefits of increased patient adherence to screening and the ease of testing, it is
reasonable to offer non-fasting lipid testing for lower-risk individuals on a routine clinic visit and to
use fasting lipid profile testing for higher-risk patients.
Lifestyle modification
For motivated patients with a 10-year risk of ASCVD > 7.5%, 3-6 months of therapeutic lifestyle
changes can be attempted before statin initiation for primary prevention. The 2013 ACC/AHA
guidelines recommend the following dietary practices for patients who would benefit from a lower
LDL-C:32
Diet high in vegetables, fruits, and whole grains
Low-fat dairy products
Protein primarily from fish, legumes, and poultry
Healthy fats (vegetable oils and nuts)
Limit sugar-sweetened beverages and red meats
Only 5-6% of calories should come from saturated fat
Reduce percentage of calories from trans fat
For more detailed guidance, see the following recommended diets to lower LDL-C:
DASH diet https://www.nhlbi.nih.gov/health/health-topics/topics/dash
USDA diet http://fnic.nal.usda.gov/dietary-guidance/dietary-guidelines
AHA diet http://www.heart.org/HEARTORG/GettingHealthy/NutritionCenter/Nutrition-
Center_UCM_001188_SubHomePage.jsp
9
The recommended exercise regimen for patients wanting to lower LDL-C:
Moderate to vigorous intensity aerobic exercise 3-4 times per week lasting on average
40 minutes per session
Moderate intensity exercise is defined as: 3-6 metabolic equivalent of tasks (METS): e.g., walking
briskly (3-5 miles per hour), bicycling slower than 10 miles per hour, yoga, gardening. Vigorous
intensity is defined as ≥ 6 METS: e.g., race walking (> 5 miles per hour), jogging, swimming laps,
bicycling faster than 10 miles per hour.
BOTTOM LINE: for patients with a 10-year risk of ASCVD > 7.5%, attempt therapeutic
lifestyle changes for 3-6 months before considering statin therapy. This approach should
be used for patients who are highly motivated and have an ASCVD risk that could be
reasonably reduced to < 7.5% with optimal risk factor control.
Target treatment groups for statins
The ACC/AHA guidelines identify 4 patient groups with the greatest potential benefit from statin
therapy6:
Patients with clinical ASCVD
Clinical ASCVD includes a history of prior myocardial infarction, acute coronary syndrome,
stable or unstable angina, coronary or other arterial revascularization, stroke, transient
ischemic attack, or peripheral arterial disease.
Patients with LDL levels: ≥ 190 mg/dL
Patients with primary severe elevations of LDL (≥ 190 mg/dL) have a high lifetime risk of
ASCVD and are likely to have genetic hyperlipidemia. Patients in whom a secondary cause of
hyperlipidemia is suspected should be first assessed and treated before pursuing genetic
testing. These causes include obesity, medications, hypothyroidism, and nephrotic syndrome.
Diabetic patients age 40-75 years
Statins for primary prevention in diabetics should be recommended for those with LDL levels
70-189 md/dL. Patients with levels ≥ 190 mg/dL should receive statin therapy based on level
alone, whereas using statins for primary prevention with low LDL levels (< 70 md/dL) has not
been studied.
Patients 40-75 years old at high-risk of ASCVD, defined as a 10-year risk >
7.5%
10
Patients without clinical ASCVD with LDL levels < 190 mg/dL who are 40-75 years old with an
elevated 10-year risk of ASCVD also benefit greatly from statins. Assessing risk in this
primary prevention population will be discussed in detail below. Individuals younger than 40
years or older than 75 years may also benefit from statin therapy if ASCVD risk is high,
although this population has not been traditionally included in randomized trials. In these
patients, the consideration of additional risk factors and risks of therapy is warranted (see
Figure 4).
Statin therapy
Statins are the only class of medications shown to improve mortality in primary and secondary
prevention of coronary artery disease (CAD), and their benefits also apply to elderly patients
without life-threatening co-morbid conditions.12,33
Statin Intensity
The 2013 Cholesterol Guidelines classified statins according to the degree by which they reduce
LDL levels (Table 4). On average, high intensity statins will reduce LDL levels by ≥ 50% whereas
moderate intensity statins will reduce LDL levels by 30% to 50%.
Table 4. Classification of statins by degree to which they reduce LDL
High-intensity statins Moderate-intensity statins Low-intensity statins
Lowers LDL by ≥ 50% Lowers LDL by 30-50% Lowers LDL by < 30%
Atorvastatin 40-80 mg*
Rosuvastatin 20-40 mg**
Atorvastatin 10-20 mg
Rosuvastatin 5-10 mg**
Simvastatin 20-40 mg
Pravastatin 40-80 mg
Lovastatin 40 mg
Fluvastatin 40mg BID
Fluvastatin XL 80 mg
Simvastatin 10 mg
Pravastatin 10-20 mg
Lovastatin 20 mg
Fluvastatin XL 20-40 mg
* Atorvastatin 80 mg daily is preferred but 40mg daily can be used if higher dose not tolerated
** All statins available as generic except Rosuvastatin (Crestor)
Patients with clinical ASCVD should receive a high-intensity statin. In certain circumstances, such
as age > 75 years or concern about side effects, a moderate-intensity statin can be used.
BOTTOM LINE: Because equipotent doses of statins appear equally effective and equally
safe, which statin to prescribe should be based primarily on the amount of LDL lowering
required to achieve the desired goal, and on affordability for the patient.
11
Statin treatment algorithms
The figures below from the 2013 ACC/AHA guidelines may help guide the use of statins and the
choice of statin intensity. Figure 3 provides a treatment strategy for patients with clinical ASCVD,
very high LDL levels, or diabetes. Figure 4 is an algorithm for treating patients with statins for
primary prevention of ASCVD.
Figure 3. Statin treatment algorithm for patients with clinical ASCVD, very high LDL levels,
or diabetes mellitus6
12
Figure 4: Statin treatment primary prevention algorithm for patients at high risk for
ASCVD6
Treatment goals
Most studies evaluating the treatment impact of statin therapy have used fixed doses of statin
therapy to lower levels of LDL cholesterol. Few studies titrated statin dose to reach a target level;
in these cases, total cholesterol levels were usually targeted. Based on treatment strategies
studied in RCTs, the 2013 Cholesterol Guidelines do not recommend titrating statin dose to a
specific LDL level. Instead, the guidelines suggest measuring a baseline LDL level and then
monitoring LDL for the percentage LDL reduction from that baseline expected with the statin used
as a way to assess patient adherence to the statin.6
13
Statin initiation and follow-up
Recommended baseline and follow-up labs are presented in Table 5 below.
Table 5: Recommended baseline and follow-up labs
Recommended lab testing
Prior to statin initiation Fasting lipid panel and ALT level
4-12 weeks after statin initiation Fasting lipid panel
Up to every 12 months thereafter Fasting lipid panel
As needed lab testing
Creatine Kinase (CK) Check at baseline in patients at high risk of myopathy
(personal or family history of muscle disease, statin
intolerance, or medications that increase risk). Check during
follow-up if muscle symptoms or generalized fatigue
ALT Check during follow-up if evidence of hepatoxicity
On follow-up lipid panel testing, evaluate for anticipated therapeutic response: LDL decrease by >
50% for high intensity statin or 30-50% for moderate intensity statin. If a patient has a smaller
response and therapy is tolerated, assess adherence to lifestyle changes and medication
regimen. In some cases, screening for secondary causes of hyperlipidemia will be necessary. If
improvement in adherence does not improve LDL response, some patients may benefit from non-
statin therapy to lower cholesterol (see section on non-statin therapies below).
Adverse Effects
Adverse effects associated with statin use tend to be dose-related. Although monitoring for
hepatotoxicity was previously recommended for patients taking statin, the actual incidence of new
liver disease was so low that this approach was not beneficial. Patients should be screened for
normal liver function before starting a statin.
Muscle related symptoms
Statins are safe and generally well-tolerated. Randomized controlled trials found little to no
excess muscle adverse event rates, such as rhabdomyolysis or myalgias.34
A rare but serious
side effect of statins is statin-associated myopathy, affecting 1 per 1000 to 1 per 10,000 people
on standard dose statins.34
In contrast to RCTs, patient registries have demonstrated that up to
29% of patients experience statin-associated muscle symptoms with higher rates of statin
14
discontinuation or non-adherence.35
Among patients with statin-associated muscle symptoms
who discontinue therapy, over 90% are ultimately able to tolerate the same statin or a different
statin with careful reintroduction and monitoring.36
If unexplained severe muscle symptoms or fatigue develop during statin therapy, promptly
discontinue the statin and address the possibility of rhabdomyolysis by evaluating CK and
creatinine and performing urinalysis for myoglobinuria.
If mild to moderate muscle symptoms develop during statin therapy:6
Discontinue the statin until the symptoms can be evaluated.
Evaluate the patient for other conditions that might increase the risk for muscle
symptoms (e.g., hypothyroidism, reduced renal or hepatic function, rheumatologic
disorders such as polymyalgia rheumatica, steroid myopathy, vitamin D deficiency, or
primary muscle diseases).
If muscle symptoms resolve, and if no contraindication exists, give the patient the original
or a lower dose of the same statin to establish a causal relationship between the muscle
symptoms and statin therapy.
If a causal relationship exists, discontinue the original statin. Once muscle symptoms
resolve, use a low dose of a different statin.
Once a low dose of a statin is tolerated, gradually increase the dose as tolerated.
If, after 2 months without statin treatment, muscle symptoms or elevated CK levels do
not resolve completely, consider other causes of muscle symptoms
If persistent muscle symptoms are determined to arise from a condition unrelated to
statin therapy, or if the predisposing condition has been treated, resume statin therapy at
the original dose.
Patients who are intolerant to this strategy may ultimately tolerate alternate day or twice-weekly
dosing strategies.37
Alternatively, patients may need to be treated with non-statin therapies,
depending on the clinical indication.
The 2013 AHA/ACC guidelines do not recommend routine creatine kinase (CK) testing for
patients receiving statins, however such measurement is reasonable for those thought to be at
risk for adverse muscle events because of a personal or family history of statin intolerance or
muscle disease, clinical presentation, or concomitant drug therapy that might increase the risk of
myopathy.6 Measuring CK levels is also reasonable in patients with muscle pain, tenderness,
stiffness, cramping, weakness, or general fatigue.6
Diabetes
Statin treatment appears to increase the incidence of diabetes by a very small amount. This
increased risk is generally out-weighed by the benefit derived from statin use.
In a subgroup analysis of the Cholesterol Treatment Trialists (CTT) meta-analysis of 14 statin
trials including 71,370 non-diabetic participants, there was one extra case of diabetes over 4
years for every 255 people treated with statin.38
In the same studies statin treatment resulted in a
15
reduction of 5.4 major coronary events (coronary mortality and non-fatal myocardial infarction)
per 255 patients treated for the same period of time.38
In an analysis of the JUPITER trial a total of 134 vascular events or deaths were avoided for
every 54 new cases of diabetes diagnosed.39
When compared to 6095 participants without risk
factors for diabetes, there was a 52% reduction in primary endpoints (HR 0.48; 95% CI: 0.33–
0.68) but no new cases of diabetes. It was calculated that the use of statins accelerated the
average time to diagnosis of diabetes by 5.4 weeks.39
Although the absolute risk of causing new-onset diabetes with statins is low, the risk of incident
diabetes needs to be considered whenever statins are prescribed. Individuals receiving statin
therapy should be evaluated for new-onset diabetes according to the current diabetes screening
guidelines.6 Those who develop diabetes during statin therapy should be encouraged to adhere
to a heart-healthy dietary pattern, engage in physical activity, achieve and maintain a healthy
body weight, cease tobacco use, and continue statin therapy to reduce their risk of ASCVD
events.6
Cognitive impairment
Concerns have been raised about the association between statin use and memory loss or
cognitive impairment. Meta-analyses of RCTs have not confirmed that statins negatively impact
memory; however such changes could have been underreported.40
Although the literature is
inconclusive, the FDA has acknowledged that statins may be associated with cognitive
impairment in rare cases, though causality is not certain.41
The expert panel of the 2013
ACC/AHA cholesterol guidelines did not find evidence that statins had an adverse effect on
cognitive changes or risk of dementia.6
Guidelines for minimizing adverse effects
The 2013 AHA/ACC guidelines suggest that the following characteristics may predispose patients
to statin adverse effects:6
Multiple or serious comorbidities, including impaired renal or hepatic function.
History of previous statin intolerance or muscle disorders
Unexplained hepatic transaminase (ALT) elevations ≥3 times upper limit of normal
Patient characteristics or concomitant use of drugs affecting statin metabolism
Age >75 years
History of hemorrhagic stroke
Asian ancestry
The following recommendations can increase the safety of statin use:6
Perform baseline ALT measure before initiating a statin
Measure hepatic function if symptoms suggest hepatotoxicity (e.g., unusual fatigue or
weakness, loss of appetite, abdominal pain, dark-colored urine, yellowing of skin or
sclera)
Consider decreasing statin dose when 2 consecutive values of LDL-C levels are 40
mg/dL
Avoid initiating simvastatin at 80 mg daily or increasing simvastatin dose to 80 mg daily
16
Use caution prescribing statins in patients 75 years or older
Use caution prescribing statins in patients taking concomitant medications that alter drug
metabolism or who are taking multiple/complex medications.
Evaluate patients presenting with a confusional state or memory impairment while on
statin therapy for non-statin causes such as exposure to other drugs and systemic
neuropsychiatric causes, in addition to considering the possibility of adverse effects
associated with statin therapy
Have patients avoid grapefruit juice since this may increase risk of side effects
BOTTOM LINE: Although statins are associated with a small increased risk of new-onset
diabetes, the benefit of treatment will be greater for many patients. Serious muscle events
associated with statins are rare but muscle complaints are common. Patients should be
monitored closely and asked about these effects, and steps should be taken quickly to
assess the full dimensions of symptoms. If an association is found with statins, options
include temporarily stopping drug and restarting at a reduced or switching to another
statin.
Non-statin therapies
Table 6 summarizes data for both statins and the available non-statin drugs, which can be
considered in patients who are either intolerant of statins or who lack the anticipated response to
statins despite adequate adherence.
Table 6. Efficacy and clinical characteristics of lipid-lowering drugs42,22
LDL Reduction
HDL increase
Cardiovascular risk reduction Major side effects
Bile acid sequestrants
15-30% Minimal No significant reduction Nausea, bloating, cramping; impairs absorption of other drugs
Fibrates 5-20% 5-20% 13% relative reduction in coronary events; no significant reduction in mortality
43
Increased creatinine, myopathy. Should not be co-administered with statin.
Nicotinic acid 10-25% 15-35% No significant reduction Flushing, pruritus, nausea, myopathy, hepatotoxicity. Should not be co-administered with statin.
44
Ezetimibe 10-20% Minimal 6% relative reduction in combined CV events after acute coronary syndrome
45
Myopathy, elevated transaminases when used with statin.
PCSK9 Inhibitors
60% 6% More than 50% relative reduction in all-cause mortality and MI in early studies
46
Myalgia, neurocognitive effects, injection site reactions (uncommon)
17
The authors of the 2013 AHA/ACC guidelines found no data supporting the routine use of non-
statin drugs combined with statin therapy to further reduce ASCVD events,6 although those
guidelines were written prior to the publication of results from the IMPROVE-IT trial and many of
the PCSK9 inhibitor trials.
Ezetimibe
The IMPROVE-IT trial studied the incremental benefit of adding ezetimibe to simvastatin therapy
in patients recently hospitalized for an acute coronary syndrome.45
The addition of ezetimibe to
simvastatin lowered LDL-C by an additional 24% at one year, compared to simvastatin alone
among patients with available lab data. The study also examined the impact of combination
therapy on a combined endpoint of cardiovasular death, major coronary event, or non-fatal
stroke. The rates of the primary end-point were 32.7% in the ezetimibe plus simvastatin group
compared to 34.7% in the simvastatin group at 7 years, a 6% relative reduction in events (HR
0.94, 95% CI 0.89, 0.99, p=0.016).
Figure 5. Ezetimibe plus simvastatin versus simvastatin alone in reducing combined
cardiac events45
18
PCSK9 Inhibitors
Proprotein convertase subtilisin kexin 9 (PCSK9) is a protease produced predominately in the
liver that facilitates the breakdown of hepatocyte LDL receptors and causes decreased clearance
of LDL cholesterol. PCSK9 inhibitors are monoclonal antibodies that are injected subcutaneously
that inhibit PCSK9 and significantly lower serum LDL levels.
Two PCSK9 inhibitors, evolocumab and alirocumab, have been tested in several phase 2 and
phase 3 clinical trials. The majority of trials have tested the combination of PCSK9 inhibitor with
statin compared to statin alone. Some trials have focused on the comparison with ezetimibe or
the combination of ezetimibe plus statin. The GAUSS trials specifically have focused on statin
intolerant patients.47
On average, the PCSK9 inhibitors reduce baseline LDL levels by nearly 60% compared to no
PCSK9 inhibitor.46
This degree of LDL reduction holds true even for patients on baseline
moderate or high-intensity statins. When compared to ezetimibe, PCSK9 inhibitors reduce LDL by
36%.46
Early evidence suggests that PCSK9 inhibitors significantly reduce the risk of CV events, even for
patients on statin therapy, however the duration of follow-up has been limited. The ODYSSEY
LONG TERM trial followed 2341 patients at high risk for CV events treated with maximally
tolerated dose of statin for 78 weeks. In addition to background statin therapy, patients were
randomized to receive alirocumab (150mg every 2 weeks) or placebo injection. Alirocumab
reduced LDL by 62% compared to placebo and had higher rates of injection-site reactions,
myalgia, neurocognitive events, and ophthalmologic events. In a post-hoc analysis, the combined
endpoint rate of CV events (death from coronary heart disease, non-fatal MI, fatal or non-fatal
stroke, or unstable angina) in the alirocumab group compared to placebo was 1.7% versus 3.3%
(HR 0.52, 95% CI 0.31 - 0.90, p=0.02).48
Similar results were found in the unblinded OSLER trial, which compared evolocumab plus
standard therapy compared to standard therapy alone. Standard therapy was based on local
guidelines for LDL treatment; 70% of patients were on concomitant statin therapy. After a median
follow-up time of 11 months, the combined rate of CV events (death, MI, unstable angina,
coronary revascularization, stroke, TIA, or heart failure) in the evolocumab group was 0.95%
compared to 2.18% in the standard therapy alone group (HR 0.47, 95% CI 0.28-0.78, p=0.003).
Neither of these trials were powered to detect a significant difference in mortality. However, a
recent meta-analysis of 24 PCSK9 phase 2 and phase 3 trials demonstrated a 55% relative
decrease in the odds of all-cause mortality (OR 0.45, 95% CI 0.23- 0.86, p=0.015).46
The FDA approved both alirocumab and evolocumab in July 2015 for patients with heterozygous
familial hypercholesterolemia (HeFH) or patients with clinical ASCVD who require additional
lowering of LDL cholesterol. A year’s supply of medication is estimated to cost over $14,000 in
the United States. Given the high cost and the need by biweekly or monthly injections, it is likely
that use of PCSK9 inhibitors will initially be limited to patients at highest ASCVD risk, their long-
term role in treatment is likely to emerge in the coming years.
19
Clinical scenarios
Should I change the statin dose for patients with clinical ASCVD on a low- or moderate-intensity statin?
Continue current dose if baseline LDL-C has been reduced by ≥ 50% or if the LDL-C < 70 mg/dL
Increase statin intensity if baseline LDL-C has been reduced by < 50% or the LDL-C ≥ 70 mg/dL
Should I change the statin dose for patients without clinical ASCVD and on a low- or moderate-intensity statin?
Continue current dose if baseline LDL-C has been reduced by at least 30-50% or if the LDL-C < 100 mg/dL
Increase statin intensity if baseline LDL-C has been reduced by < 30% or the LDL-C ≥ 100 mg/dL
Should I start/stop statin therapy in patients older than 75 years?
Continue statin therapy in patients already on a statin if currently tolerating it
Start moderate-intensity statin in patients with clinical ASCVD
Consider starting moderate-intensity statin for primary prevention after consideration of comorbidities, drug-drug interactions, and patient preferences
Have low threshold to stop statin if there are any safety concerns
Conclusions
Hyperlipidemia is one of the risk factors for coronary artery disease and a contributor to CV
mortality and morbidity. The use of statins has been proven to reduce CV outcomes in both
primary and secondary prevention studies. Statin use remains the best-tested therapy to have a
clinically relevant outcome. Although there is evidence that statin use can be associated with
myalgia and may raise the risk of developing type 2 diabetes, this risk is generally out-weighed by
the benefit derived from statin use.
20
References 1. IMS Institute for Healthcare Informatics. Medicines Use and Spending Shifts. A review of
the use of medicines in the U.S. in 2014. Parsippany, NJ April, 2015.
2. Pearson TA, Laurora I, Chu H, Kafonek S. The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med. 2000;160(4):459-467.
3. Centers for Disease C, Prevention. Vital signs: prevalence, treatment, and control of high levels of low-density lipoprotein cholesterol--United States, 1999-2002 and 2005-200. MMWR Morb Mortal Wkly Rep. 2011;60(4):109-114.
4. Lopez-Jimenez F, Simha V, Thomas RJ, et al. A summary and critical assessment of the 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: filling the gaps. Mayo Clin Proc. 2014;89(9):1257-1278.
5. Goff DC, Jr., Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(25 Suppl 2):S49-73.
6. Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(25 Suppl 2):S1-45.
7. Stamler J, Wentworth D, Neaton JD. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA. 1986;256(20):2823-2828.
8. Oklahoma State Department of Health. Heart Disease in Oklahoma. Chronic Disease Service; September 2014.
9. Jensen MD, Ryan DH, Apovian CM, et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. J Am Coll Cardiol. 2014;63(25 Pt B):2985-3023.
10. Jenkins DJ, Jones PJ, Lamarche B, et al. Effect of a dietary portfolio of cholesterol-lowering foods given at 2 levels of intensity of dietary advice on serum lipids in hyperlipidemia: a randomized controlled trial. JAMA. 2011;306(8):831-839.
11. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344(8934):1383-1389.
12. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med. 1996;335(14):1001-1009.
21
13. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995;333(20):1301-1307.
14. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA. 1998;279(20):1615-1622.
15. Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003;361(9364):1149-1158.
16. Taylor F, Ward K, Moore TH, et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2011(1):CD004816.
17. Cholesterol Treatment Trialists C, Mihaylova B, Emberson J, et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012;380(9841):581-590.
18. Marchioli R, Marfisi RM, Carinci F, Tognoni G. Meta-analysis, clinical trials, and transferability of research results into practice. The case of cholesterol-lowering interventions in the secondary prevention of coronary heart disease. Arch Intern Med. 1996;156(11):1158-1172.
19. Wilt TJ, Bloomfield HE, MacDonald R, et al. Effectiveness of statin therapy in adults with coronary heart disease. Arch Intern Med. 2004;164(13):1427-1436.
20. Gould AL, Rossouw JE, Santanello NC, Heyse JF, Furberg CD. Cholesterol reduction yields clinical benefit: impact of statin trials. Circulation. 1998;97(10):946-952.
21. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366(9493):1267-1278.
22. National Cholesterol Education Program Expert Panel on Detection E, Treatment of High Blood Cholesterol in A. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106(25):3143-3421.
23. Ridker PM, Paynter NP, Rifai N, Gaziano JM, Cook NR. C-reactive protein and parental history improve global cardiovascular risk prediction: the Reynolds Risk Score for men. Circulation. 2008;118(22):2243-2251, 2244p following 2251.
24. Ridker PM, Buring JE, Rifai N, Cook NR. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. Jama. 2007;297(6):611-619.
25. D'Agostino RB, Sr., Vasan RS, Pencina MJ, et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation. 2008;117(6):743-753.
26. Viera AJ, Sheridan SL. Global risk of coronary heart disease: assessment and application. American family physician. 2010;82(3):265-274.
22
27. DeFilippis AP, Young R, Carrubba CJ, et al. An analysis of calibration and discrimination among multiple cardiovascular risk scores in a modern multiethnic cohort. Annals of internal medicine. 2015;162(4):266-275.
28. Hayward RA. Should family physicians follow the new ACC/AHA cholesterol treatment guideline? Not completely: why it is right to drop LDL-C targets but wrong to recommend statins at a 7.5% 10-year risk. American family physician. 2014;90(4):223-224.
29. Pursnani A, Massaro JM, D'Agostino RB, Sr., O'Donnell CJ, Hoffmann U. Guideline-Based Statin Eligibility, Coronary Artery Calcification, and Cardiovascular Events. JAMA. 2015;314(2):134-141.
30. Helfand M, Carson S. Screening for Lipid Disorders in Adults: Selective Update of 2001 US Preventive Services Task Force Review. Rockville (MD)2008.
31. Sidhu D, Naugler C. Fasting time and lipid levels in a community-based population: a cross-sectional study. Arch Intern Med. 2012;172(22):1707-1710.
32. Eckel RH, Jakicic JM, Ard JD, et al. 2013 AHA/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(25 Suppl 2):S76-99.
33. Heart Protection Study Collaborative G. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360(9326):7-22.
34. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group. JAMA. 1991;265(24):3255-3264.
35. Stroes ES, Thompson PD, Corsini A, et al. Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. European heart journal. 2015;36(17):1012-1022.
36. Zhang H, Plutzky J, Skentzos S, et al. Discontinuation of statins in routine care settings: a cohort study. Ann Intern Med. 2013;158(7):526-534.
37. Keating AJ, Campbell KB, Guyton JR. Intermittent nondaily dosing strategies in patients with previous statin-induced myopathy. The Annals of pharmacotherapy. 2013;47(3):398-404.
38. Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet. 2010;375(9716):735-742.
39. Ridker PM, Pradhan A, MacFadyen JG, Libby P, Glynn RJ. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet. 2012;380(9841):565-571.
40. Ott BR, Daiello LA, Dahabreh IJ, et al. Do statins impair cognition? A systematic review and meta-analysis of randomized controlled trials. Journal of general internal medicine. 2015;30(3):348-358.
41. Wagstaff LR, Mitton MW, Arvik BM, Doraiswamy PM. Statin-associated memory loss: analysis of 60 case reports and review of the literature. Pharmacotherapy. 2003;23(7):871-880.
23
42. Ballantyne CM, Houri J, Notarbartolo A, et al. Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Circulation. 2003;107(19):2409-2415.
43. Jun M, Foote C, Lv J, et al. Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet. 2010;375(9729):1875-1884.
44. Group HTC, Landray MJ, Haynes R, et al. Effects of extended-release niacin with laropiprant in high-risk patients. The New England journal of medicine. 2014;371(3):203-212.
45. Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. The New England journal of medicine. 2015;372(25):2387-2397.
46. Navarese EP, Kolodziejczak M, Schulze V, et al. Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies in Adults With Hypercholesterolemia: A Systematic Review and Meta-analysis. Ann Intern Med. 2015;163(1):40-51.
47. Stroes E, Colquhoun D, Sullivan D, et al. Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab. J Am Coll Cardiol. 2014;63(23):2541-2548.
48. Robinson JG, Farnier M, Krempf M, et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. The New England journal of medicine.
2015;372(16):1489-1499.